Search

Your search keyword '"Spicer, James"' showing total 1,098 results
Start Over Author "Spicer, James"
1,098 results on '"Spicer, James"'

1. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer

Author

Hughes, Daniel Johnathan, Josephides, Eleni, O’Shea, Robert, Manickavasagar, Thubeena, Horst, Carolyn, Hunter, Sarah, Tanière, Philippe, Nonaka, Daisuke, Van Hemelrijck, Mieke, Spicer, James, Goh, Vicky, Bille, Andrea, Karapanagiotou, Eleni, and Cook, Gary J. R.

Published
2024
Full Text
View/download PDF

2. Reactive Laser Synthesis of Ultra-high-temperature Ceramics HfC, ZrC, TiC, HfN, ZrN, and TiN for Additive Manufacturing

Author

Peters, Adam B., Wang, Chuhong, Zhang, Dajie, Hernandez, Alberto, Nagle, Dennis C., Mueller, Tim, and Spicer, James B.

Subjects
Condensed Matter - Materials Science
Abstract

Ultra-high-temperature ceramics (UHTCs) are optimal structural materials for applications that require extreme temperature resilience, resistance to chemically aggressive environments, wear, and mechanical stress. Processing UHTCs with laser-based additive manufacturing (AM) has not been fully realized due to a variety of obstacles. In this work, selective laser reaction sintering (SLRS) techniques were investigated for the production of near net-shape UHTC ceramics such as HfC, ZrC, TiC, HfN, ZrN, and TiN. Group IV transition metal and metal oxide precursor materials were chemically converted and reaction-bonded into layers of UHTCs using single-step selective laser processing in CH4 or NH3 gas that might be compatible with prevailing powder bed fusion techniques. Conversion of either metals (Hf, Zr and Ti) or metal oxides (HfO2, ZrO2, and TiO2) particles was first investigated to examine reaction mechanisms and volume changes associated with SLRS of single-component precursor systems. SLRS processing of metal or metal oxide alone produced near stoichiometric UHTC phases with yields up to 100 wt% total for carbides and nitrides. However, for single component precursors, gas-solid reactivity induced volumetric changes resulted in residual stresses and cracking in the product layer. To mitigate conversion-induced stresses, composite metal/metal oxide precursors were employed to compensate for the volume changes of either the metal (which expands during conversion) or the metal oxide precursor (which contracts)., Comment: 58 pages, 17 figures

Published
2022

3. Selective Laser Reaction Synthesis of SiC, Si$_3$N$_4$ and HfC/SiC Composites for Additive Manufacturing

Author

Peters, Adam B., Zhang, Dajie, Hernandez, Alberto, Wang, Chuhong, Nagle, Dennis C., Mueller, Tim, and Spicer, James B.

Subjects
Condensed Matter - Materials Science
Abstract

Selective laser reaction sintering techniques (SLRS) techniques were investigated for the production of near net-shape non-oxide ceramics including SiC, Si$_3$N$_4$, and HfC/SiC composites that might be compatible with prevailing powder bed fusion additive manufacturing processes. Reaction bonded layers of covalent ceramics were produced using in-situ reactions that occur during selective laser processing and layer formation. During SLRS, precursor materials composed of metal and/or metal oxide powders were fashioned into powder beds for conversion to non-oxide ceramic layers. Laser-processing was used to initiate simultaneous chemical conversion and local interparticle bonding of precursor particles in CH4 or NH3 gases. Several factors related to the reaction synthesis process (precursor chemistry, gas-solid and gas-liquid synthesis mechanisms, precursor vapor pressures) were investigated in relation to resulting microstructures and non-oxide yields. Results indicated that the volumetric changes which occurred during in-situ conversion of single component precursors negatively impacted the surface layer microstructure. To circumvent the internal stresses and cracking that accompanied the conversion of Si or Hf (that expands upon conversion) or SiO$_x$ (that contracts during conversion), optimized ratios of the precursor constituents were used to produce near isovolumetric conversion to the product phase. The results demonstrate that under appropriate processing conditions and precursor selection, the formation of near net-shape SiC and SiC composites might be achieved through single-step AM-compatible techniques., Comment: 31 pages, 11 figures

Published
2022

4. Reactive Two-Step Additive Manufacturing of Ultra-high Temperature Carbide Ceramics

Author

Peters, Adam B., Zhang, Dajie, Nagle, Dennis C., and Spicer, James B.

Subjects
Condensed Matter - Materials Science
Abstract

Ultra-high-temperature ceramics (UHTCs) are candidate structural materials for applications that require resiliency to extreme temperature (>2000{\deg}C), high mechanical loads, or aggressive oxidizing environments. Processing UHTC transition metal carbides as standalone materials using additive manufacturing (AM) methods has not been fully realized due to their extremely slow atomic diffusivities that impede sintering and large volume changes during indirect AM that can induce defect structures. In this work, a two-step, reactive AM approach was studied for the formation of the ultra-high temperature ceramic TiCx. Readily available equipment including a polymer powder bed fusion AM machine and a traditional tube furnace were used to produce UHTC cubes and lattice structures with sub-millimeter resolution. This processing scheme incorporated, (1) selective laser sintering of a Ti precursor mixed with a phenolic binder for green body shaping, and (2) ex-situ, isothermal gas-solid conversion of the green body in CH4 to form TiCx structures. Reactive post-processing in CH4 resulted in up to 98.2 wt% TiC0.90 product yield and a reduction in net-shrinkage during consolidation due to the volume expansion associated with the conversion of Ti to TiC. Results indicated that reaction bonding associated with the Gibbs free energy release associated with TiC formation produced interparticle adhesion at low furnace processing temperatures. The ability to bond highly refractory materials through this type of process resulted in structures that were crack-free and resisted fracture during thermal shock testing. Broadly, the additive manufacturing approach presented could be useful for the production of many UHTC carbides that might otherwise be incompatible with prevailing AM techniques that do not include reaction synthesis., Comment: 23 pages,14 figures, one figure with link to external video

Published
2022

7. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Author

Spicer, James, Basu, Bristi, Montes, Ana, Banerji, Udai, Kristeleit, Rebecca, Miller, Rowan, Veal, Gareth J., Corrigan, Christopher J., Till, Stephen J., Figini, Mariangela, Canevari, Silvana, Barton, Claire, Jones, Paul, Mellor, Sarah, Carroll, Simon, Selkirk, Chris, Nintos, George, Kwatra, Vineet, Funingana, Ionut-Gabriel, Doherty, Gary, Gould, Hannah J., Pellizzari, Giulia, Nakamura, Mano, Ilieva, Kristina M., Khiabany, Atousa, Stavraka, Chara, Chauhan, Jitesh, Gillett, Cheryl, Pinder, Sarah, Bax, Heather J., Josephs, Debra H., and Karagiannis, Sophia N.

Published
2023
Full Text
View/download PDF

8. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

Author

Chauhan, Jitesh, Grandits, Melanie, Palhares, Lais C. G. F., Mele, Silvia, Nakamura, Mano, López-Abente, Jacobo, Crescioli, Silvia, Laddach, Roman, Romero-Clavijo, Pablo, Cheung, Anthony, Stavraka, Chara, Chenoweth, Alicia M., Sow, Heng Sheng, Chiaruttini, Giulia, Gilbert, Amy E., Dodev, Tihomir, Koers, Alexander, Pellizzari, Giulia, Ilieva, Kristina M., Man, Francis, Ali, Niwa, Hobbs, Carl, Lombardi, Sara, Lionarons, Daniël A., Gould, Hannah J., Beavil, Andrew J., Geh, Jenny L. C., MacKenzie Ross, Alastair D., Healy, Ciaran, Calonje, Eduardo, Downward, Julian, Nestle, Frank O., Tsoka, Sophia, Josephs, Debra H., Blower, Philip J., Karagiannis, Panagiotis, Lacy, Katie E., Spicer, James, Karagiannis, Sophia N., and Bax, Heather J.

Published
2023
Full Text
View/download PDF

9. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

11. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Author

Bax, Heather J., Chauhan, Jitesh, Stavraka, Chara, Santaolalla, Aida, Osborn, Gabriel, Khiabany, Atousa, Grandits, Melanie, López-Abente, Jacobo, Palhares, Lais C. G. F., Chan Wah Hak, Charleen, Robinson, Alexandra, Pope, Amy, Woodman, Natalie, Naceur-Lombardelli, Cristina, Malas, Sadek, Coumbe, Jack E. M., Nakamura, Mano, Laddach, Roman, Mele, Silvia, Crescioli, Silvia, Black, Anna M., Lombardi, Sara, Canevari, Silvana, Figini, Mariangela, Sayasneh, Ahmad, Tsoka, Sophia, FitzGerald, Kevin, Gillett, Cheryl, Pinder, Sarah, Van Hemelrijck, Mieke, Kristeleit, Rebecca, Ghosh, Sharmistha, Montes, Ana, Spicer, James, Karagiannis, Sophia N., and Josephs, Debra H.

Published
2023
Full Text
View/download PDF

16. Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.

Author

Dulloo, Sean, primary, Lord, Simon, additional, Fennell, Dean Anthony, additional, Thistlethwaite, Fiona, additional, Maskell, Nick, additional, Popat, Sanjay, additional, Blyth, Kevin G, additional, Szlosarek, Peter Wojciech, additional, Aujayeb, Avinash, additional, Javed, Sohail Rooman, additional, Herrero Colomina, Julio, additional, Cunniff, Brian, additional, Duncan, Jarrett, additional, Graham, Philippa, additional, Bexon, Alice Susannah, additional, Naumov, George N, additional, and Spicer, James F., additional

Published
2024
Full Text
View/download PDF

18. 126 Exploring Real-World Treatment Patterns and Outcomes in Stage IIIA N2 Non-Small Cell Lung Cancer (NSCLC)

Author

Josephides, Eleni, primary, Dunn, Roberta, additional, Faranghi, Mona, additional, Henry, Annie-Rose, additional, Pilling, John, additional, Harrison-Phipps, Karen, additional, Ahmad, Shahreen, additional, Skwarski, Michael, additional, Taylor, Benjamin, additional, Spicer, James, additional, Georgiou, Alexandros, additional, Ghosh, Sharmistha, additional, Santis, George, additional, Breen, Ronan, additional, Van Hemelrijck, Mieke, additional, Karapanagiotou, Eleni, additional, Smith, Daniel, additional, and Bille, Andrea, additional

Published
2024
Full Text
View/download PDF

19. 204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

Author

Ghorani, Ehsan, primary, Quartagno, Matteo, additional, Blackhall, Fiona, additional, O'Brien, Mary, additional, Ottensmeier, Christian, additional, Pizzo, Elena, additional, Spicer, James, additional, Gilbert, Duncan, additional, Baker, Alex, additional, Badman, Philip, additional, Milner-Watts, Charlotte, additional, D. d'Arienzo, Paolo, additional, Dangoor, Adam, additional, Adhikaree, Jason, additional, Evans, Joanne, additional, Leite, Pollyanna, additional, Keni, Manjusha, additional, Steele, Nicola, additional, Gomes, Fabio, additional, Gomez-Randulfe, Igor, additional, Belitei, Petru, additional, Stewart, Grant, additional, Barrie, Colin, additional, Geldart, Tom, additional, Jain, Pooja, additional, Liu, Justin KH, additional, Zubairi, Ishtaiq, additional, Muthukumar, Dakshinamoorthy, additional, Gray, Lucy, additional, Treece, Sarah, additional, Aleksic, Aleksandar, additional, Tsaknis, Georgios, additional, Rathbone, Emma, additional, Shaw, Paul, additional, Tarver, Kathryn, additional, Parmar, Mahesh K.B., additional, and Seckl, Michael J., additional

Published
2024
Full Text
View/download PDF

21. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

Author

Banna, Giuseppe Luigi, Addeo, Alfredo, Zygoura, Panagiota, Tsourti, Zoi, Popat, Sanjay, Curioni-Fontecedro, Alessandra, Nadal, Ernest, Shah, Riyaz, Pope, Anthony, Fisher, Patricia, Spicer, James, Roy, Amy, Gilligan, David, Gautschi, Oliver, Janthur, Wolf-Dieter, López-Castro, Rafael, Roschitzki-Voser, Heidi, Dafni, Urania, Peters, Solange, and Stahel, Rolf A.

Published
2022
Full Text
View/download PDF

22. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Author

Kindler, Hedy L, Novello, Silvia, Bearz, Alessandra, Ceresoli, Giovanni L, Aerts, Joachim G J V, Spicer, James, Taylor, Paul, Nackaerts, Kristiaan, Greystoke, Alastair, Jennens, Ross, Calabrò, Luana, Burgers, Jacobus A, Santoro, Armando, Cedrés, Susana, Serwatowski, Piotr, Ponce, Santiago, Van Meerbeeck, Jan P, Nowak, Anna K, Blumenschein, George, Jr, Siegel, Jonathan M, Kasten, Linda, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Hassan, Raffit, and Fennell, Dean A

Published
2022
Full Text
View/download PDF

24. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.

Author

Hughes, Daniel Johnathan, Josephides, Eleni, O'Shea, Robert, Manickavasagar, Thubeena, Horst, Carolyn, Hunter, Sarah, Tanière, Philippe, Nonaka, Daisuke, Van Hemelrijck, Mieke, Spicer, James, Goh, Vicky, Bille, Andrea, Karapanagiotou, Eleni, and Cook, Gary J. R.

Subjects
PROGRAMMED death-ligand 1, POSITRON emission tomography, NON-small-cell lung carcinoma, LEAN body mass, COMPUTED tomography
Abstract

Background: Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 expression are closely associated, and studies demonstrate correlation of PD-L1 with glucose metabolism. Aim: The aim of this study was to investigate the association of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) metabolic parameters with PD-L1 expression in primary lung tumour and lymph node metastases in resected NSCLC. Methods: We conducted a retrospective analysis of 210 patients with node-positive resectable stage IIB–IIIB NSCLC. PD-L1 tumour proportion score (TPS) was determined using the DAKO 22C3 immunohistochemical assay. Semi-automated techniques were used to analyse pre-operative [18F]FDG-PET/CT images to determine primary and nodal metabolic parameter scores (including max, mean, peak and peak adjusted for lean body mass standardised uptake values (SUV), metabolic tumour volume (MTV), total lesional glycolysis (TLG) and SUV heterogeneity index (HISUV)). Results: Patients were predominantly male (57%), median age 70 years with non-squamous NSCLC (68%). A majority had negative primary tumour PD-L1 (TPS < 1%; 53%). Mean SUVmax, SUVmean, SUVpeak and SULpeak values were significantly higher (p < 0.05) in those with TPS ≥ 1% in primary tumour (n = 210) or lymph nodes (n = 91). However, ROC analysis demonstrated only moderate separability at the 1% PD-L1 TPS threshold (AUCs 0.58–0.73). There was no association of MTV, TLG and HISUV with PD-L1 TPS. Conclusion: This study demonstrated the association of SUV-based [18F]FDG-PET/CT metabolic parameters with PD-L1 expression in primary tumour or lymph node metastasis in resectable NSCLC, but with poor sensitivity and specificity for predicting PD-L1 positivity ≥ 1%. Clinical relevance statement: Whilst SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters may not predict programmed death-ligand 1 positivity ≥ 1% in the primary tumour and lymph nodes of resectable non-small cell lung cancer independently, there is a clear association which warrants further investigation in prospective studies. Trial registration: Non-applicable Key Points: • Programmed death-ligand 1 immunohistochemistry has a predictive role in non-small cell lung cancer immunotherapy; however, it is both heterogenous and dynamic. • SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) metabolic parameters were significantly higher in primary tumour or lymph node metastases with positive programmed death-ligand 1 expression. • These SUV-based parameters could potentially play an additive role along with other multi-modal biomarkers in selecting patients within a predictive nomogram. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms

Author

Zareian, Nahid, primary, Eremin, Oleg, additional, Pandha, Hardev, additional, Baird, Richard, additional, Kwatra, Vineet, additional, Funingana, Gabriel, additional, Verma, Chandan, additional, Choy, Desmond, additional, Hargreaves, Steven, additional, Moghimi, Pejvak, additional, Shepherd, Adrian, additional, Lobo, Dileep N., additional, Eremin, Jennifer, additional, Farzaneh, Farzin, additional, Kordasti, Shahram, additional, and Spicer, James, additional

Published
2024
Full Text
View/download PDF

28. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

Author

Pinato, David James, primary, Jones, Robert Hugh, additional, Forster, Martin D., additional, Joshua, Anthony M., additional, Korolewicz, James, additional, Benafif, Sarah, additional, Aboud, Karam, additional, Liu, Jia (Jenny), additional, Cosman, Rasha, additional, Paull, Jeremy, additional, Fairley, Jacinth, additional, Edmondson, Stephanie Ruth, additional, and Spicer, James F., additional

Published
2024
Full Text
View/download PDF

30. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Author

Monin, Leticia, Laing, Adam G, Muñoz-Ruiz, Miguel, McKenzie, Duncan R, del Molino del Barrio, Irene, Alaguthurai, Thanussuyah, Domingo-Vila, Clara, Hayday, Thomas S, Graham, Carl, Seow, Jeffrey, Abdul-Jawad, Sultan, Kamdar, Shraddha, Harvey-Jones, Elizabeth, Graham, Rosalind, Cooper, Jack, Khan, Muhammad, Vidler, Jennifer, Kakkassery, Helen, Sinha, Shubhankar, Davis, Richard, Dupont, Liane, Francos Quijorna, Isaac, O'Brien-Gore, Charlotte, Lee, Puay Ling, Eum, Josephine, Conde Poole, Maria, Joseph, Magdalene, Davies, Daniel, Wu, Yin, Swampillai, Angela, North, Bernard V, Montes, Ana, Harries, Mark, Rigg, Anne, Spicer, James, Malim, Michael H, Fields, Paul, Patten, Piers, Di Rosa, Francesca, Papa, Sophie, Tree, Timothy, Doores, Katie J, Hayday, Adrian C, and Irshad, Sheeba

Published
2021
Full Text
View/download PDF

31. The Evolving Landscape of Cancer Therapeutics

Author

Khan, Madeha, Spicer, James, Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Rosenthal, Walter, Editorial Board Member, and Wang, KeWei, Editorial Board Member

Published
2019
Full Text
View/download PDF

35. Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer

Author

Fenwick, John D., Landau, David B., Baker, Angela T., Bates, Andrew T., Eswar, Chinnamani, Garcia-Alonso, Angel, Harden, Susan V., Illsley, Marianne C., Laurence, Virginia, Malik, Zafar, Mayles, William Philip M., Miles, Elizabeth, Mohammed, Nazia, Spicer, James, Wells, Paula, Vivekanandan, Sindu, Mullin, Anne-Marie, Hughes, Laura, Farrelly, Laura, Ngai, Yenting, and Counsell, Nicholas

Published
2020
Full Text
View/download PDF

36. 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

Author

Melero, Ignacio, primary, Baradji, Maria Lostes, additional, Spanggaard, Iben, additional, Lee, Dae, additional, Spicer, James, additional, Thistlethwaite, Fiona C, additional, Symeonides, Stefan, additional, Oh, Do-Youn, additional, Hollebecque, Antoine, additional, Rusterholz, Corinne, additional, Cirovic, Olivera, additional, Zhao, Yvonne, additional, Kratochwil, Nicole, additional, Reis, Bernhard, additional, Epp, Alexandra, additional, Kazantzidis, Georgios, additional, and Moreno, Victor, additional

Published
2023
Full Text
View/download PDF

39. List of contributors

Author

Azam, Faisal, primary, Bax, Heather J., additional, Berzofsky, Jay A., additional, Bozzato, Dania, additional, Burghaus, Rolf, additional, Castiello, Luciano, additional, Chenoweth, Alicia, additional, Cheung, Anthony, additional, Cleland, Jon, additional, Crescioli, Silvia, additional, de Visser, Saco, additional, Dieterle, Frank, additional, Ernst, Steffen W., additional, Ferber, Georg, additional, Fernandes, João C., additional, Fishburn, C. Simone, additional, Glimm, Ekkehard, additional, Granados Moreno, Palmira, additional, High, Kevin P., additional, Hoffmann, Ricarda M., additional, Jin, Ping, additional, Johnson, Rebecca, additional, Joly, Yann, additional, Justice, Jamie, additional, Karagiannis, Sophia N., additional, Kerr, David J., additional, Knight, Richard, additional, Kounnis, Valentinos, additional, Kritchevsky, Stephen, additional, Lacy, Katie E., additional, Lippert, Jörg, additional, Maeng, Hoyoung M., additional, Marincola, Francesco M., additional, Meisel, Andreas, additional, Mergenthaler, Philipp, additional, Meyer-Lindenberg, Andreas, additional, Midgley, Rachel, additional, Nakamura, Mano, additional, Newport, Rhiana, additional, Padoan, Andrea, additional, Pauli, Chantal, additional, Pereira, David M., additional, Phillips, Rachel, additional, Planas-Paz, Lara, additional, Plebani, Mario, additional, Ren, Jiaqiang, additional, Royle, Jenny, additional, Sabatino, Marianna, additional, Schwarz, Emanuel, additional, Shao, Lipei, additional, Spicer, James F., additional, Stephenson, Laura, additional, Stingl, Julia Carolin, additional, Stroncek, David F., additional, Thurston, David E., additional, Tost, Heike, additional, Truebel, Hubert, additional, Tsoka, Sophia, additional, von Degenfeld, Georges, additional, Wang, Ena, additional, Wehling, Martin, additional, and Willmann, Stefan, additional

Published
2021
Full Text
View/download PDF

40. The National Lung Matrix Trial of personalized therapy in lung cancer

Author

Middleton, Gary, Fletcher, Peter, Popat, Sanjay, Savage, Joshua, Summers, Yvonne, Greystoke, Alastair, Gilligan, David, Cave, Judith, O’Rourke, Noelle, Brewster, Alison, Toy, Elizabeth, Spicer, James, Jain, Pooja, Dangoor, Adam, Mackean, Melanie, Forster, Martin, Farley, Amanda, Wherton, Dee, Mehmi, Manita, Sharpe, Rowena, Mills, Tara C., Cerone, Maria Antonietta, Yap, Timothy A., Watkins, Thomas B. K., Lim, Emilia, Swanton, Charles, and Billingham, Lucinda

Published
2020
Full Text
View/download PDF

41. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Author

de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, and Lassen, Ulrik

Published
2019
Full Text
View/download PDF

46. Epidemiology of Lung Cancer

Author

Repana, Dimitra, Spicer, James, Loda, Massimo, editor, Mucci, Lorelei A., editor, Mittelstadt, Megan L., editor, Van Hemelrijck, Mieke, editor, and Cotter, Maura Bríd, editor

Published
2017
Full Text
View/download PDF

48. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Author

Plummer, Ruth, Verheul, Henk M., De Vos, Filip Y. F. L., Leunen, Karin, Molife, L. Rhoda, Rolfo, Christian, Grundtvig-Sørensen, Peter, De Grève, Jacques, Rottey, Sylvie, Jerusalem, Guy, Italiano, Antoine, Spicer, James, Dirix, Luc, Goessl, Carsten, Birkett, Joseph, Spencer, Stuart, Learoyd, Maria, Bailey, Christopher, and Dean, Emma

Published
2018
Full Text
View/download PDF

50. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study

Author

Papa, Sophie, primary, Adami, Antonella, additional, Metoudi, Michael, additional, Beatson, Richard, additional, George, Molly Sarah, additional, Achkova, Daniela, additional, Williams, Evangelia, additional, Arif, Sefina, additional, Reid, Fiona, additional, Elstad, Maria, additional, Beckley-Hoelscher, Nicholas, additional, Douri, Abdel, additional, Delord, Marc, additional, Lyne, Mike, additional, Shivapatham, Dharshene, additional, Fisher, Christopher, additional, Hope, Andrew, additional, Gooljar, Sakina, additional, Mitra, Arindam, additional, Gomm, Linda, additional, Morton, Cienne, additional, Henley-Smith, Rhonda, additional, Thavaraj, Selvam, additional, Santambrogio, Alice, additional, Andoniadou, Cynthia, additional, Allen, Sarah, additional, Gibson, Victoria, additional, Cook, Gary J R, additional, Parente-Pereira, Ana C, additional, Davies, David M, additional, Farzaneh, Farzin, additional, Schurich, Anna, additional, Guerrero-Urbano, Teresa, additional, Jeannon, Jean-Pierre, additional, Spicer, James, additional, and Maher, John, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results